|
Glypican 1-6
|
Heparan sulfate |
Ischemic wound healing |
(Monteforte et al., 2016) |
| Suppressing metastasis in gastric cancer |
(Han et al., 2016) |
|
Syndecan 1-4
|
Heparan sulfate |
Diabetic wound healing |
(Das et al., 2016a; Das et al., 2016b; Das et al., 2016c) |
|
Aggrecan
|
Chondroitin sulfate, keratan sulfate |
Osteoarthritis |
(Bernhard and Panitch, 2012; Place et al., 2014a; Phillips et al., 2019; Place et al., 2014b; Sarkar et al., 2012; Sharma et al., 2013; Sharma et al., 2016; Prudnikova et al., 2017; Prudnikova et al., 2018) |
|
Decorin
|
Dermatan sulfate |
Macular degeneration, diabetic retinopathy, diabetic macular edema |
(Devore et al., 2010) |
| Corneal wound healing |
(Grisanti et al., 2005; Hill et al., 2018) |
| Anti-scarring |
(Stuart et al., 2011; Ahmed et al., 2014; Wang et al., 2016) |
| Oncosupression |
(Yang et al., 2015; Wang et al., 2016; Liu et al., 2017; Oh et al., 2017a) |
| Abdominal aortic aneurysm |
(Shen et al., 2017) |
| Vascular neointimal hyperplasia |
(Paderi et al., 2011; Scott and Panitch, 2014; Scott et al., 2017) |
|
Lumican
|
Keratan sulfate |
Corneal wound healing |
(Chakravarti, 2002; Gesteira et al., 2017) |
| Bacterial lung infections |
(Shao et al., 2012; Shao et al., 2013a) |
| Scarring |
(Yeh et al., 2005; Liu et al., 2013; Yamanaka et al., 2013; Zhao et al., 2016) |
| Melanoma |
(Zeltz et al., 2009; Pietraszek et al., 2013) |
|
Biglycan
|
Chondroitin sulfate |
Duchenne muscular dystrophy |
(Amenta et al., 2011; Ito et al., 2017; Fallon and McNally, 2018) |
|
Fibromodulin
|
Keratan sulfate |
Diabetic wounds and neuropathy |
(Jian et al., 2013; Zheng et al., 2014; Jazi et al., 2016) |
| Neointimal hyperplasia |
(Ranjzad et al., 2009) |
| Bone regeneration |
(Zheng et al., 2012; Li et al., 2016) |
| Tendon healing |
(Delalande et al., 2015) |
| Breast cancer metastasis |
(Dawoody Nejad et al., 2017) |
|
Lubricin
|
None |
Osteoarthritis |
(Iqbal et al., 2016; Lakin et al., 2019; Larson et al., 2016; Ludwig et al., 2012; Wathier et al., 2013; Lawrence et al., 2015) |
| Ocular applications, dry eye |
(Lambiase et al., 2017; Oh et al., 2017b; Samsom et al., 2018a) |
|
Perlecan
|
Heparan sulfate |
Cartilage regeneration |
(French et al., 2002; Yang et al., 2006; Jha et al., 2009; Srinivasan et al., 2012) |
| Ischemic wound healing |
(Aviezer et al., 1994; Zoeller et al., 2009) |
| Neurovascular dysfunction |
(Clarke et al., 2012; Parham et al., 2016) |
| Stroke and vascular dementia |
(Lee et al., 2011; Marcelo and Bix, 2015) |
| Neointimal hyperplasia |
(Rnjak-Kovacina et al., 2016) |
